Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy right now. On September 5, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $149 from $144 while keeping an Outperform rating on the shares. Neurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds is Buying The firm told investors in a research note that, according to its latest analysis of prescription trends, Crenessity’s strong launch is expected to con ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best drug stocks to buy right now. On September 8, BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00. Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income The analyst attributed the rating to the performance of Cobenfy, the company’s new product, in the market, stating that its growth has been stable with a modest percentage increase ...

Merck & Co., Inc. (NYSE:MRK) is one of the best drug stocks to buy right now. On September 10, Leerink Partners analyst Daina Graybosch maintained a bullish stance on Merck & Co., Inc. (NYSE:MRK), giving the stock a Buy rating. Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup The analyst gave the optimistic rating due to Merck & Co., Inc.’s (NYSE:MRK) strategic position in the competitive landscape of antibody-drug conjugates (ADCs) to treat extensive-stage small cell lung cancer ( ...

Biogen Inc. (NASDAQ:BIIB) is one of the best drug stocks to buy right now. In a report released on September 12, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biogen Inc. (NASDAQ:BIIB) and set a price target of $220.00. Biogen Inc. (BIIB): Among Small-Cap Healthcare Stocks Hedge Funds is Buying Biogen Inc. (NASDAQ:BIIB) reported total revenue of $2.6 billion in its fiscal Q2 2025 results, up 7% year-over-year. GAAP diluted EPS for the quarter reached $4.33, up 8% year-over-year. Non-G ...

We came across a bullish thesis on Upstream Bio, Inc. on Value investing subreddit by Dizzy_Drawing_2451. In this article, we will summarize the bulls’ thesis on UPB. Upstream Bio, Inc.'s share was trading at $19.97 as of September 5th. Countries with the Highest Cancer Rates in the World in 2018 Photographee.eu/Shutterstock.com Upstream Bios (UPB) is developing Verekitug, a long-acting TSLP receptor-targeted biologic that could reshape treatment in chronic respiratory diseases, including severe asthma, ...

Sagimet Biosciences Inc. (SGMT) has been beaten down lately with too much selling pressure. While the stock has lost 15.8% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and ...

Dave Ricks, chair and chief executive officer of Eli Lilly and Company speaks to the Economic Club of New York in New York City, U.S., March 12, 2024.U.S. policymakers should take note as biopharmaceutical companies pull back on investments in the U.K., Eli Lilly Chief Executive Officer Dave Ricks said in an interview with CNBC.Lilly recently paused plans to create a biotech incubator called Gateway Labs in the U.K., joining other biopharma companies that have put investments in the country on hold amid con ...

All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to form the basis of a supplemental New Drug Application (sNDA) planned for submission in Q2 2026 WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of p ...

核心观点 - Jazz Pharmaceuticals plc (JAZZ) 入选12只廉价医疗股榜单并排名第九[1] - 公司核心业务聚焦肿瘤学、神经科学和睡眠医学领域创新疗法开发与商业化[1] - 获得FDA加速批准新型口服药物Modeyso用于治疗罕见儿科脑肿瘤[2][3] - 通过管线多元化和战略扩展强化神经科学与肿瘤学领域布局[3] 产品管线进展 - Modeyso (dordaviprone) 于2025年8月6日获FDA加速批准，成为首款针对1岁以上H3 K27M突变型弥漫性中线胶质瘤患者的疗法[2][3] - 该药物针对美国年患者数约2000人的罕见脑癌群体，临床数据显示22%总体缓解率（50例患者），中位缓解持续时间达10.3个月[2] - 73%应答者维持反应超过6个月，采用每周口服胶囊给药方式[2] - 继续批准取决于正在进行的三期ACTION验证性试验结果[2] 研发战略布局 - 神经科学领域：授权引进临床前阶段癫痫药物SAN2355以强化产品组合[3] - 肿瘤学领域：推进zanidatamab三期研究用于晚期胃食管癌，同时寻求Zepzelca作为广泛期小细胞肺癌一线治疗的监管批准[3] 市场定位 - 公司被列为低成本医疗保健投资标的，专注于满足未满足医疗需求的复杂疾病领域[1] - 全球生物制药领导者地位通过多元化管线建设和战略扩展得以强化[1][3]

核心观点 - 公司专注于收购和管理已上市药物的特许权 通过特许权收入获得收益并资助生物制药行业创新[1] - 公司被列为12只廉价医疗股之一 其模式提供了一种差异化的方式通过特许权流而非直接药物开发风险来获得广泛治疗管线的投资机会[3] 财务表现 - 2025年第二季度投资组合收款增长20%至7.27亿美元 特许权收款增长11%至6.72亿美元[2] - 主要贡献来自Voranigo、Trelegy、Evrysdi和Tremfya的特许权 突显了投资组合的表现和多元化[2] 战略发展 - 2025年5月收购外部管理公司RP Management LLC 整合智力资本并简化运营 标志着向完全整合的上市公司战略演进[3] - 2025年9月初定价20亿美元高级无担保票据 以加强未来特许权收购和投资的流动性[5] - 2025年9月10日发布由德勤进行的生物制药特许权市场研究 表明在行业趋势中的领导力和积极参与[5] 业务拓展 - 2025年9月宣布与Revolution Medicines达成20亿美元融资安排 包括针对RAS成瘾癌症的第三阶段疗法daraxonrasib的合成特许权[4] - FDA批准膀胱癌基因疗法Adstiladrin触发公司获得2亿美元里程碑付款 反映对尖端疗法的投资曝光[4]